| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
PYFA Stock Overview
PT Pyridam Farma Tbk develops, produces, and sells pharmaceuticals, vitamins, supplements, and traditional herbal care products in Indonesia.
Pyridam Farma Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp1,055.00 |
| 52 Week High | Rp1,325.00 |
| 52 Week Low | Rp930.00 |
| Beta | 0.62 |
| 1 Month Change | 3.43% |
| 3 Month Change | 4.98% |
| 1 Year Change | 10.47% |
| 3 Year Change | 449.48% |
| 5 Year Change | 402.38% |
| Change since IPO | 276.79% |
Recent News & Updates
Shareholder Returns
| PYFA | ID Pharmaceuticals | ID Market | |
|---|---|---|---|
| 7D | -1.4% | -0.8% | 2.3% |
| 1Y | 10.5% | 0.5% | 17.0% |
Return vs Industry: PYFA exceeded the ID Pharmaceuticals industry which returned 1.9% over the past year.
Return vs Market: PYFA underperformed the ID Market which returned 17.3% over the past year.
Price Volatility
| PYFA volatility | |
|---|---|
| PYFA Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in ID Market | 12.0% |
| 10% least volatile stocks in ID Market | 2.9% |
Stable Share Price: PYFA is less volatile than 75% of ID stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: PYFA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 895 | Yan Gwan Lee | https://www.pyfa.co.id |
PT Pyridam Farma Tbk develops, produces, and sells pharmaceuticals, vitamins, supplements, and traditional herbal care products in Indonesia. The company operates in two segments, Pharmaceutical Products and Toll Manufacturing Services, and Medical Equipment Products. It offers medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR – extraction kit and extractor machine, speciment bag, sterile container, and tube stopper.
Pyridam Farma Fundamentals Summary
| PYFA fundamental statistics | |
|---|---|
| Market Cap | Rp564.51b |
| Earnings (TTM) | Rp5.48b |
| Revenue (TTM) | Rp630.53b |
103.0x
P/E Ratio0.9x
P/S RatioIs PYFA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PYFA income statement (TTM) | |
|---|---|
| Revenue | Rp630.53b |
| Cost of Revenue | Rp385.95b |
| Gross Profit | Rp244.58b |
| Other Expenses | Rp239.10b |
| Earnings | Rp5.48b |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.24 |
| Gross Margin | 38.79% |
| Net Profit Margin | 0.87% |
| Debt/Equity Ratio | 260.2% |
How did PYFA perform over the long term?
See historical performance and comparisonValuation
Is Pyridam Farma undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
103.03x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PYFA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate PYFA's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: PYFA is poor value based on its Price-To-Earnings Ratio (103x) compared to the ID Pharmaceuticals industry average (20.7x).
PE vs Market: PYFA is poor value based on its Price-To-Earnings Ratio (103x) compared to the ID market (18.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PYFA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PYFA is overvalued based on its Price-To-Book Ratio (3.4x) compared to the ID Pharmaceuticals industry average (2.5x).
Future Growth
How is Pyridam Farma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
15.7%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pyridam Farma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Pyridam Farma performed over the past 5 years?
Past Performance Score
1/6Past Performance Score 1/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
29.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PYFA has a high level of non-cash earnings.
Growing Profit Margin: PYFA's current net profit margins (0.9%) are lower than last year (8%).
Past Earnings Growth Analysis
Earnings Trend: PYFA's earnings have grown significantly by 29.6% per year over the past 5 years.
Accelerating Growth: PYFA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PYFA had negative earnings growth (-75.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (11.7%).
Return on Equity
High ROE: PYFA's Return on Equity (3.3%) is considered low.
Financial Health
How is Pyridam Farma's financial position?
Financial Health Score
1/6Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: PYFA's short term assets (IDR326.4B) exceed its short term liabilities (IDR251.8B).
Long Term Liabilities: PYFA's short term assets (IDR326.4B) do not cover its long term liabilities (IDR387.3B).
Debt to Equity History and Analysis
Debt Level: PYFA's net debt to equity ratio (231.7%) is considered high.
Reducing Debt: PYFA's debt to equity ratio has increased from 24.3% to 260.2% over the past 5 years.
Debt Coverage: PYFA's debt is not well covered by operating cash flow (9.1%).
Interest Coverage: PYFA's interest payments on its debt are not well covered by EBIT (0.9x coverage).
Balance Sheet
Dividend
What is Pyridam Farma current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PYFA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PYFA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PYFA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PYFA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: PYFA is not paying a notable dividend for the ID market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PYFA has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.6yrs
Average management tenure
CEO
Yan Gwan Lee
1.75yrs
Tenure
Mr. Yan Gwan Lee serves as President Director at PT Pyridam Farma Tbk since August 14, 2020. He is a senior executive based in Indonesia and Singapore with over 25 years of working experience. He has sever...
Leadership Team
Experienced Management: PYFA's management team is considered experienced (2.6 years average tenure).
Board Members
Experienced Board: PYFA's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
PT Pyridam Farma Tbk's employee growth, exchange listings and data sources
Key Information
- Name: PT Pyridam Farma Tbk
- Ticker: PYFA
- Exchange: IDX
- Founded: 1976
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: Rp564.509b
- Shares outstanding: 535.08m
- Website: https://www.pyfa.co.id
Number of Employees
Location
- PT Pyridam Farma Tbk
- Sinarmas MSIG Tower
- 12th Floor
- Jakarta
- Jakarta Raya
- 12920
- Indonesia
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/24 00:00 |
| End of Day Share Price | 2022/05/24 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.